Patients with incurable cervical cancer are to be offered a new treatment which could give them more time with their loved ones.
Keytruda, an immunotherapy drug manufactured by Merck Sharp and Dohme (MSD), is the first new treatment in 14 years approved to treat advanced cervical cancer.
It is expected that over the next three years around 400 patients will benefit from the treatment, also known as pembrolizumab.
